Big Pharma manages symptoms. This startup resolves the root cause.

For over 125 years, inflammation care has relied on symptom suppression.

Aspirin was groundbreaking in its time — but in a world plagued by chronic inflammation — we all need something better.

​Sen-Jam​ is pioneering the first true leapfrog advance in inflammatory care.

Q: What do cancer, heart disease, and rheumatoid arthritis have in common? A: Inflammation drives them all.

Inflammation is a silent epidemic, at the core of countless chronic diseases. Yet today’s treatments only mask symptoms or worse suppress the body’s immune system, leaving the root cause untouched.

Sen-Jam changes that.

With its revolutionary ​PAIR (Pleiotropic Anti-Inflammatory Remedies)​ technology, Sen-Jam comprehensively targets inflammation at its source, delivering the most transformative advance since aspirin was invented.

This isn’t just an improvement—it’s a paradigm shift.

How does Sen-Jam work?

Most therapies target single inflammatory pathways — like fighting a wildfire with a squirt gun 🔥🔫

PAIR acts like a maestro, coordinating multiple inflammatory pathways for additive, powerful results.

In a Phase 2 clinical trial for SJP-002C, PAIR demonstrated:

• Strong efficacy in treating respiratory inflammation

• An exceptional safety profile, addressing both symptoms and roo causes.

“Our approach is so simple and powerful, it’s like discovering the next aspirin — an essential solution that changes everything.

Why invest in Sen-Jam?

• Massive TAM: Inflammation underlies a wide range of diseases, driving a $125 billion market projected by 2030.

• Unprecedented Innovation: 60 patents strong, Sen-Jam’s groundbreaking platform is positioned to disrupt the $1.48T pharma industry.

• Past successful exits: Backed by a team of scientific experts and entrepreneurial veterans with a proven track record.

“This is the inflection point. Science, timing, and market demand have aligned for the biggest advance in 125 years.

Perks of investing

• Invest any amount and get ​Fractional Royalty Rights​ as annual dividends

• Bonus Incentives for Larger Investments:

  • $25k+: 10% bonus in stock

  • $50k+: 12% bonus in stock

  • $100k+: 14% bonus in stock

Note: these favorable terms sunset February 15th

Be part of the next breakthrough in healthcare.

Express interest

Click the button below to:

1. Gain access to exclusive updates

2. Take your place in shaping the future of healthcare

3. Invest in the most transformative advance in over a century

The future of inflammation care starts now.

Transform health. Transform lives. Transform your portfolio.

To learn more about Sen-Jam without giving permission to email, ​click here​.

📰 Market Headlines

Tech stocks crashed yesterday as Chinese AI startup DeepSeek rattled faith in US artificial intelligence dominance.

• The Nasdaq dropped 3%, the S&P 500 fell 1.5%, and the Dow gained 0.6%.

• Nvidia fell 17%, losing $589 billion in market value.

President Trump announced plans to eliminate DEI programs from the military via executive order today.

New Zealand eased digital nomad visas, allowing 90-day stays to boost tourism.

Israel confirmed eight Gaza hostages set for release were killed in captivity.

🎰 Alts this week

🚪 TrueCrowd shuts down

🎨 Sotheby’s art sales down 28%, new focus on Saudi Arabia

🍗 Popeyes announces ​collab with Don Julio​ tequila

💵 Rare bicentennial quarter hits $15 million valuation

⚾️ Ultimate Jewish baseball card collection up for auction

🧠 Make yourself heard

GDP comes out Thursday with a consensus of around 2.9% YoY on Kalshi. This represents a decline from 3.1% in Q3 to 3.2% a year ago.

PS, if you’re not trading on Kalshi, you’re missing out on free money.

 📊 Ideas, trends, and analysis

• New home sales rose 3.6% in December, with the median price up 2.1% to $427,000.

• Oil fell as President Trump demanded OPEC cut prices and roll back environmental restrictions.

😱 Fear and Greed Index

📊 Winners and losers

Earnings, upgrades, and acquisitions

• SoFi dropped 12.1% on weak 2025 guidance.

• AT&T climbed 6.4% despite cash flow falling 25%.

• Western Alliance beat Q4 expectations; shares rose 3%.

• Nucor posted $1.22 EPS on $7.08 billion revenue; shares dipped 2%.

Market movers

• DeepSeek's R1 model disrupted AI by matching top chatbots' performance while slashing development costs and energy use.

• The FTC sued John Deere over alleged repair monopolies raising farmer costs.

• Blackstone forecasted $210 billion in CLO sales in 2025 from increased M&A activity.

• Bridgestone announced plans to cut 1,760 jobs across the Americas and close a Tennessee plant.

🎤 What you said last time

What You Had to Say:
“You can’t trust China, this is just a fact - no one in China trusts China”

📺 What to Watch Today